Judgment of the Court (Eighth Chamber) of 28 June 2017 — Novartis Europharm Ltd v European Commission, Teva Pharma BV (C-629/15 P), Hospira UK Ltd (C-630/15 P)

(Joined Cases C-629/15 P and C-630/15 P) (1)

((Appeal - Medicinal products for human use - Marketing authorisation - Regulation (EEC) No 2309/93 - Centralised procedure at European Union level - Development of a medicinal product that was the subject of a marketing authorisation for other therapeutic indications - Separate marketing authorisation and new trade name - Directive 2001/83/EC - Second subparagraph of Article 6(1) and Article 10(1) - Concept of a ‘global marketing authorisation’ - Regulatory data protection period))

(2017/C 283/05)

Language of the case: English

Parties

Appellant: Novartis Europharm Ltd (represented by: C. Schoonderbeek, advocaat)

Other parties to the proceedings: European Commission (represented by: K. Mifsud-Bonnici, A. Sipos and M. Šimerdová, acting as Agents), Teva Pharma BV (represented by: K. Bacon QC, instructed by C. Firth, Solicitor) (C-629/15 P), Hospira UK Ltd (represented by: J. Stratford QC, instructed by E. Vickers and N. Stoate, Solicitors) (C-630/15 P)

Operative part of the judgment

The Court:

(1)  OJ C 38, 1.2.2016.